The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

Valeant Pharmaceuticals International Inc

NYSE: VRX
Last

(U.S.) $254.28

Today's change0.00 0.00%
Updated July 30 4:03 PM EDT. Delayed by at least 15 minutes.
 

Valeant Pharmaceuticals International Inc

NYSE: VRX
Last

(U.S.) $254.28

Today's change0.00 0.00%
Updated July 30 4:03 PM EDT. Delayed by at least 15 minutes.

Valeant Pharmaceuticals International Inc closed at (U.S.)$254.28.

Over the last five days, shares are unchanged, but are currently 2.20% below its 52-week high. This security has outperformed the S&P 500 by 95.05% during the last year.

Key company metrics

  • Open(U.S.) $0.00
  • Previous close(U.S.) $254.28
  • High--
  • Low--
  • Bid / Ask(U.S.) $241.31 / (U.S.) $267.45
  • YTD % change+77.68%
  • Volume0
  • Average volume (10-day)1,886,082
  • Average volume (1-month)1,650,718
  • Average volume (3-month)1,627,842
  • 52-week range(U.S.) $106.00 to (U.S.) $259.99
  • Beta1.10
  • Trailing P/E104.53×
  • P/E 1 year forward21.95×
  • Forward PEG0.71×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $2.43
Updated July 30 4:03 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+9.00%

Based on its net profit margin of 9.00%, Valeant Pharmaceuticals International Inc is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.57%Sector:Industry:
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2015Q1/2015Q4/2014Q3/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedJun 30, 201506/30/2015Mar 31, 201503/31/2015Dec 31, 201412/31/2014Sep 30, 201409/30/2014
Revenue2,7322,1912,2802,056
Total other revenue--------
Total revenue2,7322,1912,2802,056
Gross profit2,0471,6161,6901,495
Total cost of revenue685575590561
Total operating expense2,3911,6681,6721,372
Selling / general / administrative686574525504
Research & development81565959
Depreciation / amortization58536586393
Interest expense (income), net operating--------
Unusual expense (income)1779240687
Other operating expenses, total17767-232
Operating income342523608684
Interest income (expense), net non-operating-412-298-225-258
Gain (loss) on sale of assets--------
Other--------
Income before tax-65155590377
Income after tax-5275534276
Income tax, total-138156100
Net income-5374535275
Total adjustments to net income--------
Net income before extra. items-5374535275
Minority interest-1-11-1
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-5374535275
Inc. avail. to common incl. extra. items-5374535275
Diluted net income-5374535275
Dilution adjustment--00--
Diluted weighted average shares344343342341
Diluted EPS excluding extraordinary itemsvalue per share-0.150.211.560.81
Dividends per sharevalue per share--0.000.000.00
Diluted normalized EPSvalue per share0.190.342.821.01